Cargando…

Meta‐Analysis of Noncompartmental Pharmacokinetic Parameters of Ertugliflozin to Evaluate Dose Proportionality and UGT1A9 Polymorphism Effect on Exposure

Ertugliflozin, a sodium‐glucose cotransporter 2 inhibitor, is primarily metabolized via glucuronidation by the uridine 5′‐diphospho‐glucuronosyltransferase (UGT) isoform UGT1A9. This noncompartmental meta‐analysis of ertugliflozin pharmacokinetics evaluated the relationship between ertugliflozin exp...

Descripción completa

Detalles Bibliográficos
Autores principales: Marshall, Jean‐Claude, Liang, Yali, Sahasrabudhe, Vaishali, Tensfeldt, Thomas, Fediuk, Daryl J., Zhou, Susan, Krishna, Rajesh, Dawra, Vikas Kumar, Wood, Linda S., Sweeney, Kevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453771/
https://www.ncbi.nlm.nih.gov/pubmed/33813736
http://dx.doi.org/10.1002/jcph.1866
_version_ 1784570342948208640
author Marshall, Jean‐Claude
Liang, Yali
Sahasrabudhe, Vaishali
Tensfeldt, Thomas
Fediuk, Daryl J.
Zhou, Susan
Krishna, Rajesh
Dawra, Vikas Kumar
Wood, Linda S.
Sweeney, Kevin
author_facet Marshall, Jean‐Claude
Liang, Yali
Sahasrabudhe, Vaishali
Tensfeldt, Thomas
Fediuk, Daryl J.
Zhou, Susan
Krishna, Rajesh
Dawra, Vikas Kumar
Wood, Linda S.
Sweeney, Kevin
author_sort Marshall, Jean‐Claude
collection PubMed
description Ertugliflozin, a sodium‐glucose cotransporter 2 inhibitor, is primarily metabolized via glucuronidation by the uridine 5′‐diphospho‐glucuronosyltransferase (UGT) isoform UGT1A9. This noncompartmental meta‐analysis of ertugliflozin pharmacokinetics evaluated the relationship between ertugliflozin exposure and dose, and the effect of UGT1A9 genotype on ertugliflozin exposure. Pharmacokinetic data from 25 phase 1 studies were pooled. Structural models for dose proportionality described the relationship between ertugliflozin area under the plasma concentration‐time curve (AUC) or maximum observed plasma concentration (C(max)) and dose. A structural model for the UGT1A9 genotype described the relationship between ertugliflozin AUC and dose, with genotype information on 3 UGT1A9 polymorphisms (UGT1A9‐2152, UGT1A9*3, UGT1A9*1b) evaluated as covariates from the full model. Ertugliflozin AUC and C(max) increased in a dose‐proportional manner over the dose range of 0.5‐300 mg, and population‐predicted AUC and C(max) values for the 5‐ and 15‐mg ertugliflozin tablets administered in the fasted state demonstrated good agreement with the observed data. The largest change in ertugliflozin AUC was in subjects carrying the UGT1A9*3 heterozygous variant, with population‐predicted AUC (90% confidence interval) values of 485 ng·h/mL (458 to 510 ng·h/mL) and 1560 ng·h/mL (1480 to 1630 ng·h/mL) for ertugliflozin 5 and 15 mg, respectively, compared with 436 ng·h/mL (418 to 455 ng·h/mL) and 1410 ng·h/mL (1350 to 1480 ng·h/mL), respectively, in wild‐type subjects. Overall, the mean effects of the selected UGT1A9 variants on ertugliflozin AUC were within ±10% of the wild type. UGT1A9 genotype did not have any clinically meaningful effects on ertugliflozin exposure in healthy subjects. No ertugliflozin dose adjustment would be required in patients with the UGT1A9 variants assessed in this study.
format Online
Article
Text
id pubmed-8453771
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-84537712021-09-27 Meta‐Analysis of Noncompartmental Pharmacokinetic Parameters of Ertugliflozin to Evaluate Dose Proportionality and UGT1A9 Polymorphism Effect on Exposure Marshall, Jean‐Claude Liang, Yali Sahasrabudhe, Vaishali Tensfeldt, Thomas Fediuk, Daryl J. Zhou, Susan Krishna, Rajesh Dawra, Vikas Kumar Wood, Linda S. Sweeney, Kevin J Clin Pharmacol Pharmacogenomics Ertugliflozin, a sodium‐glucose cotransporter 2 inhibitor, is primarily metabolized via glucuronidation by the uridine 5′‐diphospho‐glucuronosyltransferase (UGT) isoform UGT1A9. This noncompartmental meta‐analysis of ertugliflozin pharmacokinetics evaluated the relationship between ertugliflozin exposure and dose, and the effect of UGT1A9 genotype on ertugliflozin exposure. Pharmacokinetic data from 25 phase 1 studies were pooled. Structural models for dose proportionality described the relationship between ertugliflozin area under the plasma concentration‐time curve (AUC) or maximum observed plasma concentration (C(max)) and dose. A structural model for the UGT1A9 genotype described the relationship between ertugliflozin AUC and dose, with genotype information on 3 UGT1A9 polymorphisms (UGT1A9‐2152, UGT1A9*3, UGT1A9*1b) evaluated as covariates from the full model. Ertugliflozin AUC and C(max) increased in a dose‐proportional manner over the dose range of 0.5‐300 mg, and population‐predicted AUC and C(max) values for the 5‐ and 15‐mg ertugliflozin tablets administered in the fasted state demonstrated good agreement with the observed data. The largest change in ertugliflozin AUC was in subjects carrying the UGT1A9*3 heterozygous variant, with population‐predicted AUC (90% confidence interval) values of 485 ng·h/mL (458 to 510 ng·h/mL) and 1560 ng·h/mL (1480 to 1630 ng·h/mL) for ertugliflozin 5 and 15 mg, respectively, compared with 436 ng·h/mL (418 to 455 ng·h/mL) and 1410 ng·h/mL (1350 to 1480 ng·h/mL), respectively, in wild‐type subjects. Overall, the mean effects of the selected UGT1A9 variants on ertugliflozin AUC were within ±10% of the wild type. UGT1A9 genotype did not have any clinically meaningful effects on ertugliflozin exposure in healthy subjects. No ertugliflozin dose adjustment would be required in patients with the UGT1A9 variants assessed in this study. John Wiley and Sons Inc. 2021-06-19 2021-09 /pmc/articles/PMC8453771/ /pubmed/33813736 http://dx.doi.org/10.1002/jcph.1866 Text en © 2021 The Authors. The Journal of Clinical Pharmacology published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Pharmacogenomics
Marshall, Jean‐Claude
Liang, Yali
Sahasrabudhe, Vaishali
Tensfeldt, Thomas
Fediuk, Daryl J.
Zhou, Susan
Krishna, Rajesh
Dawra, Vikas Kumar
Wood, Linda S.
Sweeney, Kevin
Meta‐Analysis of Noncompartmental Pharmacokinetic Parameters of Ertugliflozin to Evaluate Dose Proportionality and UGT1A9 Polymorphism Effect on Exposure
title Meta‐Analysis of Noncompartmental Pharmacokinetic Parameters of Ertugliflozin to Evaluate Dose Proportionality and UGT1A9 Polymorphism Effect on Exposure
title_full Meta‐Analysis of Noncompartmental Pharmacokinetic Parameters of Ertugliflozin to Evaluate Dose Proportionality and UGT1A9 Polymorphism Effect on Exposure
title_fullStr Meta‐Analysis of Noncompartmental Pharmacokinetic Parameters of Ertugliflozin to Evaluate Dose Proportionality and UGT1A9 Polymorphism Effect on Exposure
title_full_unstemmed Meta‐Analysis of Noncompartmental Pharmacokinetic Parameters of Ertugliflozin to Evaluate Dose Proportionality and UGT1A9 Polymorphism Effect on Exposure
title_short Meta‐Analysis of Noncompartmental Pharmacokinetic Parameters of Ertugliflozin to Evaluate Dose Proportionality and UGT1A9 Polymorphism Effect on Exposure
title_sort meta‐analysis of noncompartmental pharmacokinetic parameters of ertugliflozin to evaluate dose proportionality and ugt1a9 polymorphism effect on exposure
topic Pharmacogenomics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453771/
https://www.ncbi.nlm.nih.gov/pubmed/33813736
http://dx.doi.org/10.1002/jcph.1866
work_keys_str_mv AT marshalljeanclaude metaanalysisofnoncompartmentalpharmacokineticparametersofertugliflozintoevaluatedoseproportionalityandugt1a9polymorphismeffectonexposure
AT liangyali metaanalysisofnoncompartmentalpharmacokineticparametersofertugliflozintoevaluatedoseproportionalityandugt1a9polymorphismeffectonexposure
AT sahasrabudhevaishali metaanalysisofnoncompartmentalpharmacokineticparametersofertugliflozintoevaluatedoseproportionalityandugt1a9polymorphismeffectonexposure
AT tensfeldtthomas metaanalysisofnoncompartmentalpharmacokineticparametersofertugliflozintoevaluatedoseproportionalityandugt1a9polymorphismeffectonexposure
AT fediukdarylj metaanalysisofnoncompartmentalpharmacokineticparametersofertugliflozintoevaluatedoseproportionalityandugt1a9polymorphismeffectonexposure
AT zhoususan metaanalysisofnoncompartmentalpharmacokineticparametersofertugliflozintoevaluatedoseproportionalityandugt1a9polymorphismeffectonexposure
AT krishnarajesh metaanalysisofnoncompartmentalpharmacokineticparametersofertugliflozintoevaluatedoseproportionalityandugt1a9polymorphismeffectonexposure
AT dawravikaskumar metaanalysisofnoncompartmentalpharmacokineticparametersofertugliflozintoevaluatedoseproportionalityandugt1a9polymorphismeffectonexposure
AT woodlindas metaanalysisofnoncompartmentalpharmacokineticparametersofertugliflozintoevaluatedoseproportionalityandugt1a9polymorphismeffectonexposure
AT sweeneykevin metaanalysisofnoncompartmentalpharmacokineticparametersofertugliflozintoevaluatedoseproportionalityandugt1a9polymorphismeffectonexposure